Is AMGN a Buy? What to Consider in 2026

Short answer

There is no universal answer to whether AMGN is a buy; it depends on your thesis, time horizon, and what you already own. Below is the case for Amgen, the main risks to weigh, where the stock trades, and a framework to decide for yourself. This is informational, not a recommendation, and Walnut is not an investment adviser.

Amgen (AMGN) is one of the world's largest biotechnology companies, developing, manufacturing, and selling human therapeutics primarily for serious illnesses. Its portfolio spans inflammation, oncology, cardiovascular disease, bone health, and rare diseases, with well-known products that have included Enbrel, Prolia and Xgeva, Repatha, Otezla, and a growing pipeline. Amgen pioneered large-scale recombinant-protein and antibody manufacturing and is a leader in biosimilars as older biologics lose patent protection. The 2023 acquisition of Horizon Therapeutics added rare-disease drugs such as Tepezza and Krystexxa. Amgen is also developing obesity and metabolic candidates, including investigational drugs in the GLP-1 class of weight-loss therapies. Headquartered in Thousand Oaks, California, and founded in 1980, Amgen is a member of the Dow Jones Industrial Average and returns substantial cash to shareholders through a growing dividend and buybacks.

What's the case for buying AMGN?

1. Rare disease and Horizon assets.

The Horizon Therapeutics acquisition added higher-growth rare-disease drugs such as Tepezza and Krystexxa, diversifying Amgen away from older, slower-growing franchises and giving it newer products with patent runway and pricing power in specialty markets.

2. Obesity and metabolic pipeline.

Amgen is developing candidates in the obesity and metabolic space, including investigational GLP-1-class and related therapies. Success in this large and fast-growing market could provide a significant new growth driver, though the candidates must still clear late-stage trials and regulatory review.

3. Biosimilars and cash generation.

As blockbuster biologics lose exclusivity industrywide, Amgen is both defending its own products and selling biosimilars of competitors' drugs. Combined with strong free cash flow, this supports a growing dividend and buybacks, giving the stock an income and capital-return component on top of pipeline optionality.

What are the risks to AMGN?

Amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure. Drug development is high-risk: pipeline candidates, including its obesity programs, can fail in late-stage trials or face regulatory setbacks. US drug-pricing policy, including Medicare negotiation under the Inflation Reduction Act, pressures margins on key products. The Horizon acquisition added debt. Litigation, manufacturing, and safety risks are inherent to the industry. Verify the latest pipeline and revenue trends before drawing conclusions.

How is AMGN valued? (as of early 2026)

Revenue (TTM): ~$33-35 billion (approximate, verify)
Operating margin: ~30%+ (approximate, verify)
P/E (TTM): ~20-25x (GAAP varies; approximate, verify)
Dividend yield: ~3% (approximate, verify)
Market cap: ~$150 billion-plus (approximate, verify)
Net debt: Elevated after the Horizon acquisition (verify)
Index membership: Dow Jones Industrial Average, S&P 500, Nasdaq-100

Amgen trades at a moderate multiple typical of a mature large-cap biopharma, reflecting steady cash flow and a meaningful dividend balanced against patent-cliff and drug-pricing risk. The valuation embeds expectations for the rare-disease and obesity pipelines to offset declines in older franchises. All figures are approximate and move with the share price and reported results; verify current numbers before relying on them.

How do you decide if AMGN is a buy?

Rather than asking whether AMGN is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold AMGN indirectly through an index or sector ETF before adding more.

For the full picture, see the AMGN stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about AMGN against your real portfolio and see your actual exposure before deciding.

The bottom line on AMGN

Whether AMGN is a buy is not a universal verdict; it comes down to your thesis, your time horizon, and what you already own. Amgen has a real case (above) and real risks to weigh. If you believe the thesis, the questions that matter are position sizing and overlap, not market timing. Walnut can show how AMGN sits against your actual holdings before you decide. It is not an investment adviser.

Build a basket around AMGN with Walnut

Use Amgen as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.

Create a free Walnut account

FAQ

Is AMGN a good stock to buy right now?

There is no universal answer. Whether Amgen fits depends on your thesis, time horizon, risk tolerance, and what you already own. This page lays out the case for, the main risks, and where the stock trades, so you can decide for yourself. Walnut is not an investment adviser and this is not a recommendation.

What does Amgen do?

One of the world's largest biotech companies, with a broad biologics portfolio plus growing rare-disease, biosimilar, and obesity pipelines.

What are the main risks of AMGN?

What is Amgen's (AMGN) ticker symbol?

AMGN, listed on Nasdaq. Officially Amgen Inc. Founded in 1980 and headquartered in Thousand Oaks, California. It is a member of the Dow Jones Industrial Average, the S&P 500, and the Nasdaq-100, and trades during US market hours at every major US brokerage.

What does Amgen (AMGN) do?

Amgen is a large biotechnology company that develops, manufactures, and sells biologic medicines for serious illnesses across inflammation, oncology, cardiovascular disease, bone health, and rare diseases. Products have included Enbrel, Prolia, Xgeva, Repatha, Otezla, and rare-disease drugs from the Horizon acquisition such as Tepezza. It also develops biosimilars and a pipeline that includes obesity candidates.

Who are Amgen's (AMGN) main competitors?

Across therapeutic areas, Pfizer, Merck, AbbVie, Bristol Myers Squibb, Johnson and Johnson, Novartis, and Roche. In obesity, its candidates would compete with Eli Lilly and Novo Nordisk. In biosimilars, with Sandoz, Samsung Bioepis, Teva, and others.

Is Amgen (AMGN) a good dividend stock?

Descriptive, not a recommendation. Amgen pays a meaningful and growing dividend, with a yield around 3% as of early 2026, supported by strong free cash flow. Income-oriented investors often view it as a dividend-paying large-cap biopharma, but dividends are not guaranteed and the stock carries patent-cliff and pipeline risk. Walnut is informational, not investment advice.

Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell AMGN; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.